By Rohit Schroff

The popularity of mass spectrometry based testing is growing all the time. As a result, businesses in the diagnostics industry offering mass-spectrometry-based clinical assays, especially analytical laboratories in toxicology environments, are facing a number of major challenges. These include meeting scaling requirements that are non-linear, overcoming regulatory uncertainties while guaranteeing business continuity, raising ROI on LC/MS instruments and lowering turnaround times.

So, if your business is offering mass-spectrometry-based tests, how do you make sure it continues to run smoothly and increase profitability for the long-term? In this short, powerful film, Rohit Shroff, Head of Sales Development, EMEA for the Life Science Markets at Tecan, offers a single, simple answer.

See what Rohit has to say now.

Challenges for diagnostic industry using mass spectrometry assays 




About the author

Rohit Schroff

Rohit Shroff has been with Tecan for 5 years and is Head of Sales Development, EMEA for the life science business. He received a Ph.D. in Analytical Chemistry from the Max Planck Institute for Chemical Ecology, Germany and went on to do a postdoc in high throughput proteomics at the ETH in Zurich. Rohit worked as an R&D scientist at the Nestle Research Centre in Lausanne before joining Tecan. At Tecan he has held a variety of positions as an applications specialist, a product manager and now in his current role overseeing marketing and applications in the EMEA market.

Manually related articles